Published in Curr Opin Pharmacol on October 01, 2004
High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem Biol (2007) 1.85
Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A (2007) 1.70
Gain of glycosylation in integrin α3 causes lung disease and nephrotic syndrome. J Clin Invest (2012) 1.66
Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention. J Med Chem (2007) 1.58
Enhancing functional production of G protein-coupled receptors in Pichia pastoris to levels required for structural studies via a single expression screen. Protein Sci (2006) 1.46
Regions of melanocortin 2 (MC2) receptor accessory protein necessary for dual topology and MC2 receptor trafficking and signaling. J Biol Chem (2008) 1.36
Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs. Trends Endocrinol Metab (2009) 1.12
Structure and function of the melanocortin2 receptor accessory protein (MRAP). Mol Cell Endocrinol (2008) 1.10
Regulation of G protein-coupled receptor signaling: specific dominant-negative effects of melanocortin 2 receptor accessory protein 2. Sci Signal (2010) 1.08
Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro. Mol Cell Endocrinol (2007) 1.08
Pharmacochaperone-mediated rescue of calcium-sensing receptor loss-of-function mutants. Mol Endocrinol (2009) 1.04
GABA acts as a ligand chaperone in the early secretory pathway to promote cell surface expression of GABAA receptors. Brain Res (2010) 1.04
Functional rescue of beta-adrenoceptor dimerization and trafficking by pharmacological chaperones. Traffic (2009) 1.03
Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol Pharmacol (2010) 1.00
Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J Am Soc Nephrol (2009) 0.99
Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Mol Cell Endocrinol (2008) 0.98
Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2. Biochemistry (2010) 0.96
Enhancement of the surface expression of G protein-coupled receptors. Trends Biotechnol (2009) 0.94
Plasma membrane expression of GnRH receptors: regulation by antagonists in breast, prostate, and gonadotrope cell lines. J Endocrinol (2008) 0.93
Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors. Adv Pharmacol (2011) 0.91
Behind the curtain: cellular mechanisms for allosteric modulation of calcium-sensing receptors. Br J Pharmacol (2012) 0.89
Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs. PLoS One (2011) 0.89
Synthesis and characterization of a new fluorogenic substrate for alpha-galactosidase. Anal Bioanal Chem (2009) 0.88
Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor. PLoS One (2013) 0.87
Pediatric disorders of water balance. Pediatr Clin North Am (2011) 0.83
Importance of extracellular loop one of the neuropeptide S receptor for biogenesis and function. Peptides (2009) 0.83
Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors. Recent Pat Endocr Metab Immune Drug Discov (2011) 0.81
Evidence that small molecule enhancement of β-hexosaminidase activity corrects the behavioral phenotype in Dutch APP(E693Q) mice through reduction of ganglioside-bound Aβ. Mol Psychiatry (2014) 0.80
14-3-3ζ Protein regulates anterograde transport of the human κ-opioid receptor (hKOPR). J Biol Chem (2012) 0.80
Using pharmacological chaperones to restore proteostasis. Pharmacol Res (2014) 0.79
Monitoring G protein-coupled receptor and β-arrestin trafficking in live cells using enhanced bystander BRET. Nat Commun (2016) 0.79
Chaperone-like effects of cell-permeant ligands on opioid receptors. Front Biosci (Landmark Ed) (2009) 0.79
Visualization of G protein-coupled receptor (GPCR) interactions in living cells using bimolecular fluorescence complementation (BiFC). Curr Protoc Neurosci (2010) 0.78
Pediatric disorders of water balance. Endocrinol Metab Clin North Am (2009) 0.77
Neuronal gamma-aminobutyric acid (GABA) type A receptors undergo cognate ligand chaperoning in the endoplasmic reticulum by endogenous GABA. Front Cell Neurosci (2015) 0.77
Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function. Mol Cell Endocrinol (2013) 0.77
Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism. Br J Pharmacol (2014) 0.76
Src regulates sequence-dependent beta-2 adrenergic receptor recycling via cortactin phosphorylation. Traffic (2014) 0.76
N-Glycan-dependent and -independent quality control of human δ opioid receptor N-terminal variants. J Biol Chem (2014) 0.75
The Pharmacochaperone Activity of Quinine on Bitter Taste Receptors. PLoS One (2016) 0.75
Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A (2003) 3.75
Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol (2010) 3.64
Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol (2002) 3.45
Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J Biol Chem (2002) 3.40
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med (2006) 3.38
Roles of G-protein-coupled receptor dimerization. EMBO Rep (2004) 3.33
Real-time monitoring of receptor and G-protein interactions in living cells. Nat Methods (2005) 2.72
Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol (2006) 2.69
Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci (2005) 2.63
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat Struct Mol Biol (2006) 2.62
The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci (2007) 2.46
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
Real-time monitoring of ubiquitination in living cells by BRET. Nat Methods (2004) 2.23
Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J (2005) 2.16
Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol (2005) 2.14
Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. EMBO J (2002) 2.13
Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem (2005) 2.10
Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem (2010) 2.06
Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting. J Biol Chem (2004) 2.03
Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab (2004) 1.96
Mutant Frizzled 4 associated with vitreoretinopathy traps wild-type Frizzled in the endoplasmic reticulum by oligomerization. Nat Cell Biol (2003) 1.96
Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem (2003) 1.96
Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J (2005) 1.90
Restructuring G-protein- coupled receptor activation. Cell (2012) 1.83
Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney Int (2012) 1.81
Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int (2012) 1.77
Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol (2002) 1.76
Ethnic differences in renal responses to furosemide. Hypertension (2008) 1.74
Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem (2002) 1.68
Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep (2005) 1.65
High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. J Biomol Screen (2005) 1.61
Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem (2002) 1.59
Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol (2005) 1.57
Insights into signaling from the beta2-adrenergic receptor structure. Nat Chem Biol (2008) 1.56
Role of palmitoylation/depalmitoylation reactions in G-protein-coupled receptor function. Pharmacol Ther (2003) 1.55
Receptor activity-independent recruitment of betaarrestin2 reveals specific signalling modes. EMBO J (2004) 1.55
BRET analysis of GPCR oligomerization: newer does not mean better. Nat Methods (2007) 1.48
Heterotrimeric G proteins form stable complexes with adenylyl cyclase and Kir3.1 channels in living cells. J Cell Sci (2006) 1.46
A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci Signal (2011) 1.45
Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J Biol Chem (2002) 1.44
Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1). J Biol Chem (2003) 1.44
Homo- and hetero-oligomerization of beta-arrestins in living cells. J Biol Chem (2005) 1.39
Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J Biol Chem (2004) 1.39
Nephrogenic diabetes insipidus. Ann Intern Med (2006) 1.38
Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. Proc Natl Acad Sci U S A (2004) 1.38
Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. J Biol Chem (2008) 1.34
Phosphorylation-independent desensitization of GABA(B) receptor by GRK4. EMBO J (2003) 1.30
Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways. Mol Pharmacol (2009) 1.30
Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. Mol Pharmacol (2008) 1.29
Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat Disord (2004) 1.27
Monitoring protein-protein interactions in living cells by bioluminescence resonance energy transfer (BRET). Curr Protoc Neurosci (2006) 1.26
Elaboration of a novel technique for purification of plasma membranes from Xenopus laevis oocytes. Am J Physiol Cell Physiol (2006) 1.24
G protein-coupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase. J Biol Chem (2002) 1.23
The role of the GX9GX3G motif in the gating of high voltage-activated Ca2+ channels. J Biol Chem (2006) 1.19
Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of receptor activity-modifying protein-1. J Biol Chem (2007) 1.19
Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). J Biol Chem (2011) 1.19
Quantification of ligand bias for clinically relevant β2-adrenergic receptor ligands: implications for drug taxonomy. Mol Pharmacol (2013) 1.19
Heteroligomerization of an Aquaporin-2 mutant with wild-type Aquaporin-2 and their misrouting to late endosomes/lysosomes explains dominant nephrogenic diabetes insipidus. Hum Mol Genet (2002) 1.18
The BRET2/arrestin assay in stable recombinant cells: a platform to screen for compounds that interact with G protein-coupled receptors (GPCRS). J Recept Signal Transduct Res (2002) 1.17
Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins. J Biol Chem (2008) 1.17
Heterodimerization of beta1- and beta2-adrenergic receptor subtypes optimizes beta-adrenergic modulation of cardiac contractility. Circ Res (2005) 1.17
Resonance energy transfer approaches in molecular pharmacology and beyond. Trends Pharmacol Sci (2007) 1.16
Unraveling G protein-coupled receptor endocytosis pathways using real-time monitoring of agonist-promoted interaction between beta-arrestins and AP-2. J Biol Chem (2007) 1.15
An evolutionarily conserved autoinhibitory molecular switch in ELMO proteins regulates Rac signaling. Curr Biol (2010) 1.15
Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Neurochem (2004) 1.12
Distinct subcellular localization for constitutive and agonist-modulated palmitoylation of the human delta opioid receptor. J Biol Chem (2006) 1.11
Palmitoylation of the V2 vasopressin receptor carboxyl tail enhances beta-arrestin recruitment leading to efficient receptor endocytosis and ERK1/2 activation. J Biol Chem (2003) 1.10
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol (2013) 1.10
GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics (2010) 1.09
Subcellular imaging of dynamic protein interactions by bioluminescence resonance energy transfer. Biophys J (2007) 1.08
Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Sci Signal (2012) 1.07
Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol (2008) 1.07
Receptor-regulated interaction of activator of G-protein signaling-4 and Galphai. J Biol Chem (2010) 1.07
How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta (2010) 1.06
The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling. Cell Signal (2006) 1.06
Regulation of the AGS3·G{alpha}i signaling complex by a seven-transmembrane span receptor. J Biol Chem (2010) 1.06
Cell-biologic and functional analyses of five new Aquaporin-2 missense mutations that cause recessive nephrogenic diabetes insipidus. J Am Soc Nephrol (2002) 1.06
Multimerization of Staufen1 in live cells. RNA (2010) 1.05
Reversed polarized delivery of an aquaporin-2 mutant causes dominant nephrogenic diabetes insipidus. J Cell Biol (2003) 1.05
A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer. J Virol Methods (2005) 1.04
Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics (2007) 1.04
Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol (2004) 1.04
Functional rescue of beta-adrenoceptor dimerization and trafficking by pharmacological chaperones. Traffic (2009) 1.03
Subcellular distribution of GABA(B) receptor homo- and hetero-dimers. Biochem J (2005) 1.03
Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension? Am J Physiol Renal Physiol (2010) 1.03
Impedance responses reveal β₂-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles. PLoS One (2012) 1.02
Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. J Pharmacol Exp Ther (2009) 1.01
Two novel aquaporin-2 mutations responsible for congenital nephrogenic diabetes insipidus in Chinese families. J Clin Endocrinol Metab (2002) 1.00
The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors. Am J Physiol Renal Physiol (2014) 1.00
Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J Am Soc Nephrol (2005) 1.00
Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci U S A (2013) 1.00
Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol Pharmacol (2010) 1.00
A cyclic peptide mimicking the third intracellular loop of the V2 vasopressin receptor inhibits signaling through its interaction with receptor dimer and G protein. J Biol Chem (2004) 1.00
Dynamic anal endosonography and MRI defecography in diagnosis of pelvic floor disorders: comparison with conventional defecography. Dis Colon Rectum (2011) 0.99
Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. J Pharmacol Exp Ther (2010) 0.99